Krebs Biochemicals and Industries LimitedKREBSBIOCorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Jun 2025 1 quarters of data

₹60.19

MCap ₹130 Cr

Krebs Biochemicals and Industries Limited — Stock analysis & AI research Krebs Biochemicals and Industries Limited — Seasonality — best & worst months Krebs Biochemicals and Industries Limited — Technical setup — score, trend, support & resistance Krebs Biochemicals and Industries Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹5 Cr

Sales · Jun 2025

₹-2 Cr

Operating Profit · Jun 2025

-38.1%

OPM % · Jun 2025

₹-5 Cr

Net Profit · Jun 2025

₹-2.47

EPS · Jun 2025

📝 Krebs Biochemicals and Industries Limited — results explained

Quarter ended June 2025 (Q1 FY26)

Krebs Biochemicals and Industries Limited reported revenue of ₹5 crore for the quarter ended June 2025 (Q1 FY26).

The company reported a net loss of ₹5 crore. Earnings per share (EPS) came in at ₹-2.47.

Operating profit stood at ₹-2 crore — an operating margin (OPM) of -38.1%.

Valuation snapshot

At the current price of ₹60.19, KREBSBIO has a market capitalisation of ₹130 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 10th-largest of the 11 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.74%, foreign institutional investors (FIIs) 0.50%, public shareholders 26.76% of Krebs Biochemicals and Industries Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹130 Cr

Current Price ?

₹60.2

P/E ?

N/A

Industry P/E ?

32.10

P/B ?

-0.80

P/S ?

N/A

P/FCF ?

-25.95

Enterprise Value ?

₹355 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

-15.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹5 Cr

PAT — latest qtr ?

₹-5 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹225 Cr

Debt to Equity ?

-1.39

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

72.74%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

12.1%

Return 6 months ?

-3.1%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Jun 2025	YoY %	QoQ %
Sales	5	—	—
Operating Profit	-2	—	—
Other Income	0	—	—
Interest	2	—	—
Depreciation	2	—	—
Profit Before Tax	-5	—	—
Net Profit	-5	—	—
EPS	-2.47	—	—
OPM %	-38.1%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	22	22	22	22	+0.0%
Reserves	-121	-141	-168	-184	-9.5%
Borrowings	183	194	212	225	+6.1%
Other Liabilities	91	104	103	101	-1.9%
Total Liabilities	175	178	169	163	-3.6%
Fixed Assets	147	150	146	142	-2.7%
CWIP	4	2	3	2	-33.3%
Investments	0	0	0	0	—
Other Assets	24	26	20	20	+0.0%
Total Assets	175	178	169	163	-3.6%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-25	2	-8	-2	+75.0%
Cash from Investing Activity	-13	-8	-5	-4	+20.0%
Cash from Financing Activity	37	6	13	6	-53.8%
Net Cash Flow	-0	0	0	-0	—
Free Cash Flow	-36	-5	-11	-5	+54.5%
CFO/OP	157%	-27%	52%	35%	-32.7%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	4	14	0	0	—
Inventory Days	170	543	396	—	—
Days Payable	217	1,051	1,192	—	—
Cash Conversion Cycle	-44	-494	-795	0	+100.0%
Working Capital Days	-232	-322	-787	-1,593	-102.4%
ROCE %	-29%	-19%	-30%	-15%	+50.0%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	72.74%	72.74%	72.74%	72.74%	72.74%	+0.0%
FIIs	0.50%	0.50%	0.50%	0.50%	0.50%	+0.0%
Public	26.76%	26.76%	26.76%	26.77%	26.76%	-0.0%
No. of Shareholders	9,118	8,912	8,710	8,553	8,533	-0.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SMSPHARMA SMS Pharmaceuticals	₹442.45	4,144	39.7	898	102	19.3%	11.4%	13.3%	48.6%	5.6%	-1.4%
2	AARTIDRUGS Aarti Drugs	₹428.30	3,909	20.5	2,678	191	12.4%	7.1%	7.5%	16.3%	18.9%	-7.2%
3	HIKAL Hikal	₹229.83	2,834	—	1,734	-34	13.4%	-2.0%	-8.0%	-154.4%	6.0%	67.0%
4	BETA Beta Drugs	₹2,064.90	2,084	37.5	513	57	20.5%	11.2%	—	—	25.5%	31.7%
5	NGLFINE NGL Fine-Chem	₹2,786.60	1,722	30.1	536	57	15.6%	10.6%	36.0%	123.2%	33.6%	99.1%
6	ANUHPHR Anuh Pharma	₹92.99	932	21.1	779	44	8.6%	5.7%	16.5%	-12.8%	4.2%	42.8%
7	INFINIUM Infinium Pharma	₹222.95	347	31.2	190	14	11.3%	7.2%	—	—	45.2%	166.7%
8	AAREYDRUGS Aarey Drugs	₹98.71	329	67.1	415	4	1.6%	1.0%	-0.4%	12.3%	-56.3%	-25.3%
9	PAR Par Drugs	₹128.90	159	10.9	109	14	18.3%	13.3%	2.7%	-1.9%	20.1%	41.6%
10	KREBSBIO Krebs Biochemicals	₹57.94	125	—	25	-14	-10.0%	-55.9%	-45.2%	37.1%	27.4%	53.3%
11	VILINBIO Vilin Bio	₹18.00	27	14.2	42	2	7.6%	4.6%	—	—	215.9%	1680.0%

❓ Frequently asked questions

What was Krebs Biochemicals and Industries Limited's revenue in Q1 FY26?